首页> 外文期刊>The Journal of Neuroscience: The Official Journal of the Society for Neuroscience >The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion.
【24h】

The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion.

机译:跨膜信号量Sema4D / CD100是轴突生长的抑制剂,在少突胶质细胞上表达,并在CNS病变后上调。

获取原文
获取原文并翻译 | 示例
           

摘要

Semaphorins are a family of secreted and membrane-bound proteins, known to regulate axonal pathfinding. Sema4D, also called CD100, was first isolated in the immune system where it is involved in B and T cell activation. We found that in the mouse, Sema4D is expressed in cells throughout the CNS white matter, with a peak during the myelination period. Double-labeling experiments with different markers of oligodendrocyte lineage such as olig1, olig2, platelet-derived growth factor receptor alpha, and proteolipid protein showed that Sema4D was expressed selectively by oligodendrocytes and myelin. The presence of Sema4D in myelin was confirmed using Western blot. Sema4D expression in myelinating oligodendrocytes was further observed using neuron-oligodendrocyte cocultures. Moreover, using stripe assay, we found that Sema4D is strongly inhibitory for postnatal sensory and cerebellar granule cell axons. This prompted us to examine whether Sema4D expression is modified after CNS injury. At 8 d after spinal cord lesions, Sema4D expression was strongly upregulated in oligodendrocytes at the periphery of the lesion. Sema4D-positive cells were not colabeled with the astrocyte marker GFAP, with the microglial and macrophagic marker isolectin B4, or with NG2, a marker of oligodendrocyte precursors. This upregulation was transient because from 1 month after the lesion, Sema4D expression was back to its normal level. These results indicate that Sema4D is a novel inhibitory factor for axonal regeneration expressed in myelin.
机译:信号量是分泌和膜结合蛋白的家族,已知可调节轴突寻路。 Sema4D(也称为CD100)首先在免疫系统中分离出来,并参与B和T细胞的活化。我们发现在小鼠中,Sema4D在整个中枢神经系统白质的细胞中表达,在髓鞘形成期达到峰值。使用少突胶质细胞谱系的不同标记(例如olig1,olig2,血小板衍生的生长因子受体α和蛋白脂蛋白)进行的双标记实验表明,少突胶质细胞和髓磷脂选择性表达Sema4D。使用蛋白质印迹法确认了髓磷脂中Sema4D的存在。使用神经元-少突胶质细胞共培养进一步观察到髓鞘少突胶质细胞中Sema4D表达。此外,使用条纹测定法,我们发现Sema4D对出生后的感觉和小脑颗粒细胞轴突具有强烈的抑制作用。这促使我们检查中枢神经系统损伤后Sema4D表达是否被修饰。脊髓损伤后第8天,病变周围少突胶质细胞中Sema4D的表达强烈上调。 Sema4D阳性细胞未与星形胶质细胞标记GFAP,小胶质和巨噬细胞标记异凝集素B4或NG2(少突胶质细胞前体标记)共标记。这种上调是暂时的,因为从病变后1个月开始,Sema4D表达恢复到正常水平。这些结果表明Sema4D是髓鞘中表达的轴突再生的新型抑制因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号